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Topoisomerase 1 (Top1), a nuclear enzyme involved in DNA relaxation, is the target of several anticancer drugs. TOP1 mutations
occur in camptothecin-resistant tumour cell lines. We explored, in the NCI panel of 60 human tumour cell lines, whether
polymorphic variations in the TOP1 gene could explain differences in drug sensitivity. The 21 exons of the gene were fully studied as
well as five intronic domains that had previously been shown to harbour single nucleotide polymorphisms (SNPs) or mutations. PCR
products covering the whole exonic sequences or the relevant intronic domains were subjected to denaturing high-performance
liquid chromatography. Nucleotide variations were then determined by sequencing. Discrimination between intronic common and
variant homozygous samples was performed using a restriction fragment length polymorphism technique. Only one exonic mutation
was detected, at the heterozygous state; it occurs in exon 19 of a colon cancer cell line (HCT-15) and consists of a G4A transition at
position 75, resulting in a Met675Ile change. The intronic sequences studied harboured the SNPs expected with allelic frequencies
between 20 and 40%. Three major haplotypes, generating 92% of the 10 genotypes encountered, were defined as containing none of
the intronic SNPs, or three of them, or all of them. No significant relationship was evidenced between Top1 expression and the TOP1
polymorphisms studied. However, when comparing the cytotoxicity of 138 drugs as a function of the genotypes, several drug groups,
namely Top1 inhibitors, antifolates and taxanes, had significantly different IC50s as a function of the distribution of the intronic SNPs of
the TOP1 gene.
British Journal of Cancer (2006) 95, 906–913. doi:10.1038/sj.bjc.6603361 www.bjcancer.com
Published online 19 September 2006
& 2006 Cancer Research UK
Keywords: anticancer drug cytotoxicity; camptothecins; DNA topoisomerase 1; gene polymorphisms; NCI-60 panel
                                                     
Human DNA topoisomerase I (Top1) is a monomeric nuclear
protein of 91kDa (765 amino acids) encoded by a gene located on
chromosome 20 (20q12–13.2). Topoisomerase 1 is the target
enzyme of several anticancer drugs used in the clinics (camptothe-
cins) or in development (indolocarbazoles) (Pommier et al, 1999).
Topoisomerase 1 is able to relax supercoiled DNA, downstream the
replication and transcription machineries, through the formation
of transitory single-strand breaks. During the catalytic process, a
transesterification occurs, with tyrosine 723 of the active centre
forming a covalent bond with a 30 phosphate group, allowing the
nicked DNA strand to rotate about the intact strand, and relieving
thus by one turn the torsional constraint. Topoisomerase 1 also
catalyses the religation of nicked strand, restoring DNA continuity.
Topoisomerase 1-interfering drugs convert the enzyme into a
cellular poison by inhibiting the religation step, trapping thus the
enzyme into a stable covalent DNA complex. Cytotoxic lesions are
likely to result from the collision between the replication fork and
the stabilised cleavable complex, transforming thus a single-strand
break into a double-strand break (Wang, 1994). It should be
noticed that some agents behave as catalytic inhibitors, by
inhibiting the cleavage reaction itself; none of them has been yet
developed as an anticancer agent (Pommier et al, 1998).
No functional analysis of the polymorphisms of the TOP1 gene
has been undertaken; such polymorphisms could lead to an
alteration of the level of expression and/or the activity of the
enzyme, which would explain part of the individual variability of
response to Top1 inhibitors. Mutations of the TOP1 gene have
been observed in tumour cell lines selected for resistance to
camptothecin (Takatani et al, 1997; Pommier et al, 1999; Tsurutani
et al, 2002; Woo et al, 2002) or sometimes in clinical specimens
(Ohashi et al, 1996), indicating that amino-acid changes could
have consequences on cell response to this drug. In addition, a
decreased expression of Top1 has been associated to resistance to
camptothecin (Sorensen et al, 1995); although the mechanism
involved in this decrease has not been identified, it could result
from alterations of regulatory sequences in the promoter of the
gene. Numerous functional polymorphisms have been identified in
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sdrug-metabolising enzymes or drug transporters, as well as in drug
receptors and targets (see Robert et al, 2005, for review). For
instance, a polymorphism located in the 50 untranslated domain of
thymidylate synthase, the target enzyme for fluoropyrimidines, is
associated with a change in protein expression and, consequently,
in cellular response to the drug (Pullarkat et al, 2001). Therefore,
identifying functional polymorphisms in the TOP1 gene could
prove of interest for understanding the individual variability of
drug effects.
Research and identification of functional polymorphisms in
genes involved in drug response and toxicity generally require
abundant clinical resources, with numerous patients treated with
the drug and fully documented clinical files. This is especially
difficult in oncology, because patients are often treated with drug
combinations and because the clinical end points are multiple and
sometimes difficult to record. Looking for a cellular model able to
provide clues and tracks about the functional polymorphisms of
the TOP1 gene, we decided to use the National Cancer Institute
(NCI) panel of 60 human tumour cell lines. This panel was initially
established for high-throughput screening of natural products and
synthetic molecules, on the basis of their antiproliferative proper-
ties (Monks et al, 1991). In addition, a number of molecular
markers and gene expression profiles have been determined in the
panel, allowing to establish relationships between chemo-sensitiv-
ity or -resistance and the molecular features of the cells (Scherf
et al, 2000). The inverse correlation between fluorouracil
cytotoxicity and dihydropyrimidine dehydrogenase gene expres-
sion has served as a paradigm for such studies. We and others have
developed data mining on the NCI database in order to discover
relationships between drug activity and cell molecular properties
(Robert et al, 2004; Vekris et al, 2004). It should be mentioned that
no relationship between TOP1 gene expression and camptothecin
cytotoxicity has been detected (Goldwasser et al, 1995).
No analysis of gene polymorphisms has yet been performed on
the NCI panel. As it consists of tumour cells, they can present
many somatic genetic alterations, distinct from an actual
constitutive polymorphism present in the patient who hosted the
tumour. We think, however, that the NCI panel could represent a
valuable starting point to study the role of gene point variations on
anticancer drug activity. The TOP1 gene covers about 100kb and
consists of 21 exons; 248 single nucleotide polymorphisms (SNPs)
have been referenced in databases (http://www.ncbi.nlm.nih.gov/
SNP/snp_ref.cgi?locusId¼7150), but the frequency of only 49 has
been established. One of them only is present in a coding domain
(exon 12), with a heterozygosity frequency of 0.043 in an African-
American population but it was not detected in a Caucasian
population (http://www.ncbi.nih.gov/SNP/snp_ss.cgi?subsnp_id¼
23535865). In a first step, we explored in totality the 21 exons of
the gene and the 50 untranscribed region by denaturing high-
performance chromatography. In a second step, we analysed
specifically five intronic SNPs chosen among the 15 that were
known to have a frequency higher than 0.25, localised in introns 2,
3, 6, 8 and 17, covering about 82kb. In addition to the study of
the NCI panel, we also explored the TOP1 exons of a standard
Caucasian population. The relationship between the presence of a
given SNP in the TOP1 gene of the NCI panel cell lines and the
expression of the TOP1 gene or the cytotoxicity of 138 standard
anticancer drugs was then studied, based on the publicly available
NCI databases (http://dtp.nci.nih.gov).
MATERIALS AND METHODS
Biological samples
Frozen cell pellets from 59 of the 60 NCI cell lines of the panel were
kindly provided by Dr S Holbeck, Cancer Therapeutic Branch,
NCI, Bethesda, MD, USA. One cell line, MDA-N, is no longer
available in the panel.
Genomic DNAs of a healthy Caucasian French population (53
samples) were kindly provided by the Laboratory of Genetics of
Institut Bergonie ´. All individuals had given written consent for a
scientific use of their blood samples.
Molecular biology techniques
Genomic DNA was extracted from cell pellets using QIAamp
s
DNA minikit from Qiagen (Courtaboeuf, France). It was quantified
by spectrophotometry. DNA electrophoresis was performed on
agarose gels in Tris-acetate-EDTA buffer (pH 8.0).
Polymerase chain reactions (PCR) were performed on 40ng
genomic DNA, using Platinum
s Taq polymerase (Invitrogen,
Cergy-Pontoise, France) and a GenAmp PCR system 9700
s
thermocycler (Applied Biosystems, Courtaboeuf, France). The
oligonucleotide primers were determined using the Primer 3
software, from the TOP1 gene sequence (NT_011362). They were
designed in order to cover the complete sequences of the exons,
the 50 untranscribed region up to 350 nucleotides upstream exon 1,
and, for introns, the short sequences where a SNP had been
localised (see Figure 1). Tables 1 and 2 present the sequences of the
primers used for PCR as well as the length of the PCR products.
PCR products were submitted to denaturing high-performance
liquid chromatography (dHPLC) in order to identify heterozygous
DNA samples in the TOP1 exons of the cell lines of the panel. We
used a Wave Nucleic Acid Fragment Analysis System
s (Trans-
genomic, Elancourt, France) with a ion-exchange column and a
gradient of acetonitrile in triethyl ammonium acetate buffer as a
solvent. In this system, heteroduplexes are eluted more rapidly
than homoduplexes, revealing the presence of a SNP on one DNA
strand. Homozygous variants cannot be discriminated from
homozygous common alleles with this system.
E20
E19
E21
E9 E12
E13
E15
E17
I17 I6 I3 I2 I8
5′ 3′
Figure 1 Genomic structure of the TOP1 gene. The exons (E) and introns (I) specifically mentioned in the text are indicated by arrows and they are
numbered accordingly.
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sNucleotide sequencing of PCR products was achieved using an
ABI 377 sequencer (Perkin Elmer, Courtaboeuf, France) and the
ABI PRISM Dye Terminator Cycle Sequencing
s kit (Perkin
Elmer), which uses the dideoxynucleotide technique of Sanger
et al (1977) with four different fluorochromes.
A restriction fragment length polymorphism (RFLP) technique
could be set up for four of the five known intronic SNPs, using the
same PCR primers as those used for dHPLC. This allowed the rapid
identification of homozygous (common and variant) samples for
each of the variations, as well as a confirmation for the
heterozygous samples. Table 2 lists the restriction enzymes that
were used for the digestions. All of them were purchased from
Ozyme (Saint-Quentin-en-Yvelines, France). For the variation in
intron 17, for which no restriction site could be modified by the
variation, common and variant homozygous samples were
discriminated by dHPLC of a mixture of a known common
homozygous sample with the unknown sample.
Relationships between gene polymorphisms and drug
cytotoxicity
After identification of the genotypes of each cell line, the IC50
values of 138 core drugs vis-a `-vis the 59 cell lines, expressed as
–log10(IC50), were extracted from the NCI database; mean values
were calculated for common homozygous, variant homozygous
and heterozygous cell lines for each of the variations encountered,
and were compared by analysis of variance. Drugs were then
grouped as a function of their known mechanism of action into
eight categories (see Scherf et al (2000) for details): alkylating or
platinating agents acting on N
7 of guanine; other alkylating agents,
acting on N
2 and O
6 of guanine; antimetabolites; antifolates;
topoisomerase I inhibitors; topoisomerase II inhibitors; spindle
poisons, which could be subdivided into vinca-alkaloid-type and
taxane-type mechanisms of action. Only 10 drugs out of 138
remained unclassified because of disagreement about their precise
Table 1 Primer sequences for the PCR of the 21 exons of the TOP1 gene
SNP Localisation
a Primer sequence
Exon length
(bp)
Amplicon
length (bp)
50 UTR G4709344T
rs6072250
S: GATACCAGCTCTGCCCAAGA
As: AGACTCCAGAAACGGCTGAG
— 656
Exon 1 S: CCGACGTGTTGTTTAAAAG
As: CCTAGCGAGCCGATCTAC
279 474
Exon 2 S: GGCCGCGAAGTTACAGTT
As: ACGCCATGTCTGTCCTCT
25 285
Exon 3 S: TGTCAAGGTAGGCATACAGA
As: GCTGAATGATGAGGGACTT
97 201
Exon 4 S: GGCTAACGCTTTGTGACTTA
As: CCTTCCTCCCCTACTAGAAA
124 184
Exon 5 S: CCAGGAACTGATGCTACATA
As: TTGGGTTAACTCAGACAACA
56 233
Exon 6 S: CACTCTGACCAGCAATTTTT
As: AGTTCAGAGAAATCAGTCCA
96 280
Exon 7 S: TGTATTCATGTTCCCCTTTC
As: AGCCCCAAAGGACCTAAG
76 130
Exon 8 S: GCTTTCTCACCATGTTTCTT
As: ATTTTAACCCAGTGCTGAGA
107 158
Exon 9 G4774052A (Gly214Ser)
rs6029542
S: ATCACTAAATGAGGCTGTGC
As: TCTATTACATAGGATCCTTCCTT
116 242
Exon 10 S: TCACTTTTTGGAACCACTTT
As: ACTTGATTGTTTTGCAAGGT
122 201
Exon 11 S: TCCCCATTTTCTTTTGACTA
As: ATTCCAGAATTCTCCAGAGG
123 184
Exon 12 G4781682A (Arg349Arg)
rs6029545
S: TCAGACTTTCCTCTACCTTGA
As: CTTTTTGGCCCATAGGAT
188 325
Exon 13 Gly418Lys S: TTTCACTATCCTCGTGCTCT
As: AGGTTATCAGCACCATGAAC
145 223
Exon 14 S: TGCCTGGCTATATTCAAAGT
As: GATGGGAAGATGCTCTCAC
144 238
Exon 15 G4795621A (Glu517Lys)
rs6129757
S: ATGTCTCTTCCATTCATGCT
As: ACCCATGCTTGTTGAATAAT
186 288
Exon 16 S: TGCAAGTTTCTTTAAGTTTGG
As: TTCAACATTGTGTGCTTCAT
69 181
Exon 17 G4797898A (Thr591Thr)
rs1061982
S: TTCCTCTTTCCCTAACTTCC
As: ATCTGGCCAAGCAATACTTA
115 276
Exon 18 S: GATAAGAGCCAGCAAAATCA
As: TCCTCTCATTCGCAGATAAT
128 300
Exon 19 T4803328C (Lys676Lys) S: CATCTTGGTTTCACCTTCTC
As: GCTGCACACTTTTCTCTACC
95 222
Exon 20 A4803680G (Asn722Ser) S: GGTTCTTGAGGACTTTGCTA
As: AAGGAGGGCTCAACACTTAC
150 199
Exon 21 G4804749A (splice site)
rs6072277
S: CATTGCTGAGTCACCCTAAT
As: AGTGAGGCTCAGTTTATCCA
107 224
G4804829C (Met758Ile)
rs12057885
aThis refers to mutations or SNPs mentioned in databases and that have been especially sought.
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smechanism of action. In order to compare drug groups, the
individual IC50 values were normalised by subtracting individual
values from the mean value of the 60-cell line panel. Using a
univariate general linear model, we compared the variance of the
IC50s for each genotype and we calculated the significance of the
differences in the mean IC50s of each drug group as a function of
the genotype of the cell lines. This model allows to take into
account the unbalanced size of the groups. Due to the number of
tests performed, we considered as significant only the P-values
lower than 2.5 10
 4 (Bonferroni correction). All analyses were
performed with the SPSS software (version 12.0).
RESULTS
Research of exonic SNPs
We studied by dHPLC the PCR products originating from the 21
exons explored, including the intron–exon junctions, and from the
50 untranscribed region up to 350 nucleotides before exon 1, using
the primers indicated in Table 1. The presence of heteroduplexes
was detected in only four PCR products over more than 2000
dHPLC runs that have been performed: in exon 13 of the IGROV1
cell line (ovarian cancer), in exon 17 of the MOLT-4 (leukaemia)
and KM-12 (colon cancer) cell lines, and in exon 19 of the HCT-15
line (colon cancer). We explored five exons in the control
population (exons 9, 12, 15, 19 and 21) that were selected because
they contained the variations encountered in cell lines selected
with camptothecin. No heteroduplex was detected in any of these
five exons.
After sequencing, it appeared that three of the four variations
detected in the cell lines of the NCI panel were indeed intronic, at a
short distance of the exon–intron junctions, but not involving the
splice site. The only true exonic variation observed was the one
located in exon 19 of the HCT-15 cell line; it consists of a G4A
transition at position 75 of the exon, resulting in a met4ile amino-
acid change at position 675 of the protein.
Because of the very low frequency of the heterozygous DNAs, we
found it unlikely to expect the presence of corresponding
homozygous variants in either the control population or the NCI
panel and no systematic sequencing of the PCR products was
undertaken.
Research of intronic SNPs
We first studied by dHPLC the PCR products originating from the
five introns explored, at the sites where a SNP had been mentioned
in databases with a frequency 40.25, using the primers indicated
in Table 2. There were numerous heterozygous samples in the NCI
panel. We verified, by sequencing 10 randomly selected samples
for each intron, that each variation observed was the one expected
from databases. We then set up RFLP techniques for the rapid
identification of homozygous (common and variant) samples for
each of the variations, as well as a confirmation for the
heterozygous samples. Table 3 presents the distribution of the
intronic variations among the 59 cell lines of the panel.
The frequency of the variations detected was between 20 and 40%.
It clearly appeared that there was a strong linkage disequili-
brium between the intronic variations studied. A total of 10
different genotypes were identified and, from these data, it was
possible to identify three major haplotypes and four minor
haplotypes. A major haplotype (60%) was characterised by the
absence of all the intronic variations studied, the second one (16%)
by the presence of the variations in introns 3, 6 and 17, and the
third one (20%) by the presence of all the intronic variations
studied. We propose to name these haplotypes A, B and C,
respectively. The minor haplotypes were each present in only one
cell line and contained 1–4 of the intronic variations studied. The
combinations of the three major haplotypes generated 92% of all
diplotypes and only four cell lines contained another haplotype.
Relationships between gene polymorphisms and drug
cytotoxicity
The HTC-15 cell line (colon cancer) was the only one to harbour a
non-synonymous SNP, located in exon 19. The –log(IC50)o f
camptothecin in this cell line was 6.82, as mentioned in the NCI
database, to be compared with the mean value (7s.d.) of
camptothecin –log(IC50) in the 60 cell lines of the panel
(7.3870.55). This corresponds to a 3.6-fold resistance of the
HCT-15 cell line as compared to the average cell line. Similar
findings were obtained with the other topoisomerase I inhibitors
of the camptothecin family (topotecan, SN-38). The –log(IC50)o f
rebeccamycin, the indolocarbazole lead compound tested against
the NCI panel, is 6.40 in the HCT-15 cell line, which is among the
five least sensitive cell lines of the whole panel to this agent (mean
value for the panel: 6.7070.26). It is not possible, however, to
assign a causal relationship between this relative low sensitivity
and exon 19 polymorphism, because the HTC-15 line appears as
globally chemoresistant to most anticancer drugs (Scherf et al,
2000).
We compared the mean IC50s of 138 core drugs, extracted from
the NCI database, in the three genetic status (wild-type homo-
zygous, heterozygous, variant homozygous) of each of the intronic
variation studied. Because of the small number of cell lines (3)
exhibiting intron 2 or intron 8 variations at the homozygous state,
we excluded them from the comparative study because of the
possibility of bias. Comparison was also made as a function of
the presence or absence of each of the three main haplotypes in the
genotype of the cell lines. When considered individually, none of
the 138 drugs had IC50 values significantly different according to
the genotype, after Bonferroni adjustment. We then constituted
drug groups on the basis of their mechanism of action (Scherf
et al, 2000), and compared the normalised mean IC50 values of
Table 2 Primer sequences for the PCR of the five intronic regions known as harbouring frequent SNPs
SNP Localisation
a Restriction enzyme Primer sequence Intron length (bp) PCR product length (bp)
Intron 2 T4717580C
rs1265035
BfaI S: GTAAGGTAGCCCCTTTGTTT
As: CTTTCCTGGTCTCTGGTTCT
31938 185
Intron 3 T4743257C
rs1997833
MseI S: TTAGGCCTTAAATGGGATG
As: CAAGCTTGCTACAGACTTGA
14680 163
Intron 6 T4762170C
rs6016511
MnlI S: TCCTGTCAGACATTCTAAGTGA
As: CCTTTCCATCCAATTTCTACT
984 177
Intron 8 C4768132T
rs6124314
HinP1I S: GTGGTAGTTACTCAATAAATGCT
As: AGGGCACCTAATTCTACACA
7903 156
Intron 17 A4799318G
rs6129760
— S: TCAATTCCTCGTTCTGTTCT
As: TTCATCTCCTTGCTTCCTC
1776 152
aThis refers to the variations mentioned in databases.
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sTable 3 Distribution of the intronic SNPs among the cell lines of the NCI-60 panel
Tumour type Cell line
Intron 2
rs1265035
Intron 3
rs1997833
Intron 6
rs6016511
Intron 8
rs6124314
Intron 17
rs6129760 Diplotype
a
Leukaemia CCRF-CEM HT V V HT V BC
HL-60 WWWWWA A
K-562 HT HT HT HT HT AC
M O L T - 4 WWWWWA A
RPMI-8226 HT HT V HT V
S R H T VVVV
Lung cancer A549/ATCC WWWWWA A
EKVX HT V V HT V BC
HOP-62 VVVVVC C
HOP-92 HT HT HT HT HT AC
NCI-H226 HT HT HT HT HT AC
NCI-H23 W HT HT W HT AB
NCI-H322M WWWWWA A
NCI-H460 WWWWWA A
NCI-H522 WWWWWA A
Colon cancer COLO-205 WWWWWA A
HCC-2998 WWWWWA A
HCT-116 W V V W V BB
HCT-15 WWWWWA A
HT29 W HT HT W HT AB
K M 1 2 WWWWWA A
SW-620 HT HT HT HT HT AC
Central nervous system SF-268 WWWWWA A
SF-295 W HT HT W HT AB
SF-539 WWWWWA A
SNB-19 W V V W V BB
SNB-75 WWWWWA A
U251 WWWWWA A
Melanoma LOXIMVI V HT V HT V
MALME-3M W HT HT W HT AB
M 1 4 H TH TH TH TH TA C
SK-MEL-2 WWWWWA A
SK-MEL-28 HT HT W W W
SK-MEL-5 HT HT HT HT HT AC
UACC-257 W HT HT W HT AB
UACC-62 HT HT HT HT HT AC
Ovarian cancer IGROV1 HT HT HT HT HT AC
O V C A R - 3 WWWWWA A
OVCAR-4 W V V W V BB
OVCAR-5 W HT HT W HT AB
O V C A R - 8 WWWWWA A
SK-OV-3 VVVVVB B
Renal cancer 786-0 HT HT HT HT HT AC
A 4 9 8H TH TH TH TH TA C
A C H N VVVVVC C
CAKI-1 WWWWWA A
RXF-393 WWWWWA A
SN-12C HT HT HT HT HT AC
TK-10 WWWWWA A
UO-31 W V V W V BB
Prostate cancer PC-3 HT HT HT HT HT AC
DU-145 WWWWWA A
Breast cancer MCF-7 HT HT HT HT HT AC
NCI/ADR-RES WWWWWA A
MDA-MB-231 WWWWWA A
HS578T HT HT HT HT HT AC
MDA-MB-435 HT HT HT HT HT AC
BT-549 WWWWWA A
T-47D W HT HT W HT AB
aFour diplotypes could not be ascertained due to the presence of rare haplotypes.
DNA topoisomerase 1 gene polymorphisms
F Moisan et al
910
British Journal of Cancer (2006) 95(7), 906–913 & 2006 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
seach drug group in the different genotypes. In order to avoid to
take into account apparently significant relationships between
drug sensitivity and polymorphic variations, which would result
from chance only, we exclusively considered as relevant the
differences in mean IC50 values of at least 50% (IC50 ratios 41.5 or
o0.67) (biological significance) and giving a P-value o10
 4
(statistical significance). The presence of variations in introns 2
and 8 (which are concomitant in 21 cell lines) appeared associated
to a higher sensitivity to antifolates and taxanes (Table 4), whereas
the presence of variations in introns 3, 6 and 17 (which are
concomitant in 33 cell lines) was associated to sensitivity to
topoisomerase I inhibitors and to resistance to taxanes.
When haplotypes were considered, it appeared that the presence
of at least one allele A in the genotype (47 cell lines) was
significantly associated to resistance to Top1 inhibitors and to
sensitivity to taxanes; the presence of at least one allele B (14 cell
lines) was significantly associated to sensitivity to taxanes and
antifolates; and the presence of at least one allele C (22 cell lines)
was associated to sensitivity to Top 1 inhibitors, antifolates and
taxanes (Figure 2).
We also compared the Top1 expression data, as extracted from
the NCI database, to the genetic status of the intronic variations
and of haplotype distribution. Among the various microarray data
in the NCI database (http://dtp.nci.nih.gov), those performed
independently by two groups with the U95A and the U133A
Affymetrix chips appeared as the more reliable and they were used
for comparisons with drug cytotoxicity and with TOP1 genotypes.
There was no significant correlation between TOP1 gene expres-
sion and the cytotoxicity of Top1 inhibitors vis-a `-vis the NCI-60
panel, and we found no correlations either between TOP1 gene
expression and the gene polymorphisms. As the TOP1 gene copy
number could be a confounding factor for establishing relation-
ships between gene polymorphisms and gene expression, we
corrected the expression data in the NCI database by dividing the
expression levels by the number of chromosome 20q arms in the
cell line, as extracted from the karyotype description (http://
www.ncbi.nlm.nih.gov/sky/skyweb/cgi), but we evidenced not
better relationships.
DISCUSSION
This is the first time, to our knowledge, that the genomic variations
of Top1 were studied in a variety of tumour and normal samples.
Topoisomerase 1 appears in this study as a highly conserved
protein, with exceptional variations in the coding sequence. This is
probably in relation to the crucial importance of this enzyme
activity in cell life. Only one exonic variation was found in 59
different tumour cell lines and 53 DNA samples of healthy
individuals. This variation is able to determine an amino-acid
change at position 675 of the protein, in a domain which is not far
from the catalytic tyrosine (amino acid 723) but in a linker region
where no drug-induced mutation able to confer drug resistance
has been identified (Ohashi et al, 1996; Takatani et al, 1997;
Pommier et al, 1999; Tsurutani et al, 2002; Woo et al, 2002). For
this reason, we have not tried to detect the variant protein in the
Table 4 Relationships between intronic SNPs and drug sensitivity in the cell lines of the NCI-60 panel
Top1 inhibitors (18) Antifolates (11) Taxanes (13)
IC50 ratio P-value IC50 ratio P-value IC50 ratio P-value
Intron 2
a HT vs W 1.16 0.022 2.22 8.0 10
 7 1.90 1.9 10
 11
Intron 8
a HT vs W 1.25 6.8 10
 5 2.69 5.7 10
 8 2.12 1.5 10
 12
Intron 3 V vs W 1.85 5.7 10
 8 1.39 0.86 0.46 2.8 10
 9
V vs HT 1.83 1.1 10
 7 0.79 0.037 0.34 2.1 10
 11
Introns 6 and 17
b V vs W 2.01 1.0 10
 8 2.21 0.064 0.69 2.3 10
 5
V vs HT 1.84 5.3 10
 7 1.32 0.930 0.50 1.5 10
 8
Allele A Pres. vs Abs. 1.91 6.0 10
 9 1.69 0.272 0.58 1.8 10
 9
Allele B Abs. vs Pres. 1.16 0.006 2.72 8.1 10
 7 2.21 2.6 10
 12
Allele C Abs. vs Pres. 0.70 5.0 10
 10 0.39 4.4 10
 8 0.58 1.0 10
 10
Abbreviations: Abs., absent; HT, heterozygous; Pres., present; V, variant; W: wild-type.
aDue to the small number (three) of homozygous variants for these variations,
comparisons of their IC50s with wild-type and heterozygous samples were not made.
bAll cell lines presented the same variations of introns 6 and 17.
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Figure 2 Schematic representation of the association between the presence or absence of a given allele in the genotype of the cell lines of the NCI-60
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scorresponding cell line and we do not know whether it is expressed
and whether it shares the same catalytic properties as the common
enzyme. It is also difficult to know whether this variation is a
polymorphism that can be encountered in normal subjects with
low frequency or a tumour somatic mutation generated during the
process of oncogenesis.
This is also the first report on the haplotype distribution of
TOP1 in a panel of human tumours. The most frequent intronic
variations described in the databases have been found at the
expected location and with the expected frequency. As we have
explored, from intron 2 to intron 17, about 82% of the length of the
TOP1 gene, we have obtained a global insight of the haplotype
distribution. Only three different haplotypes were present in 55 cell
lines out of 59, the four remaining cell lines harbouring different
haplotypes, in combination with the A and C haplotypes.
Haplotypes were distributed randomly among the various cell
lines, with no specificity for the tissue of origin of the tumour cell
lines, suggesting that they reflect the constitutive distribution of
the individuals from whom the tumour was isolated and grown in
culture. There was no relationship between haplotype distribution
and the cytogenetic status of the cell lines, which was studied in
detail by Roschke et al (2003) and is freely available on the NCBI
site (http://www.ncbi.nlm.nih.gov/sky/skyweb/cgi): the three main
haplotypes were present in cells which were diploid, polyploid or
aneuploid for chromosome 20, and so were also the rare
haplotypes.
The intronic SNPs of TOP1 have been determined by the
Hapmap consortium in a normal Caucasian population of 91
subjects from the Centre d’E ´tude du Polymorphisme Humain
(CEPH) (http://www.hapmap.org), 84 of whom could be assigned
as presenting a combination of the three main haplotypes A, B and
C. The frequencies of alleles A, B and C were similar in this
population and in the NCI panel. However, when considering the
distributions of A, B and C haplotypes in terms of common
homozygous, heterozygous and variant homozygous genotypes, it
appeared that the number of AB heterozygous samples was
slightly lower than expected in the NCI panel from the Hardy–
Weinberg distribution (P¼0.073). This means that a loss of
heterozygosity may have occurred during the process of onco-
genesis for allele B, but not for allele C. As a consequence, several
cell lines considered as homozygous for allele B must rather be
hemizygous for at least a part of chromosome 20. Loss of
heterozygosity is also evident from the comparisons that can be
done on cell lines which have been recently shown to originate
from the same individual (Holbeck, personal communication,
August 8, 2005; see Garraway et al, 2005): NCI/ADR-RES and
OVCAR-8, M14 and MDA-MB-231 and U251 and SNB-19. For two
of these pairs, the genotypes we identified were different, which
can only be explained by loss of heterozygosity having occurred in
one of the cell lines.
The relationships between drug cytotoxicity and the polymor-
phism of TOP1 cannot be explained by a simple effect on TOP1
gene expression or enzyme intrinsic activity, as no significant
relationship could be evidenced between the polymorphisms and
the gene expression data, even after correction by the TOP1 gene
copy number. The gene expression database of the NCI may not
appear very robust, with 10 microarray data sets obtained with
various distinct oligonucleotides, and no data set obtained with a
reference technique such as quantitative RT–PCR. We only used
the microarray data obtained with the U95A and the U133A
Affymetrix chips, which were provided by two independent groups
working on distinct RNA extracts and gave strongly correlated
results. There appears to be a lower reliability of data from the
U95B-E and U133B chips, which has been observed with many
other genes and may reflect incorrect mapping of the gene to that
Affymetrix feature. Even if we missed a correlation between TOP1
polymorphisms and Top1 expression, the mechanism by which the
corresponding haplotype would influence Top1 expression re-
mains elusive. Furthermore, the relationships between cell
sensitivity to antifolates and taxanes and the haplotype distribu-
tion of TOP1 genotypes cannot be explained at this point from a
pharmacological point of view.
It must be kept in mind that polymorphisms may only be the
reflect of unidentified variations, occurring at a distance from the
SNP studied, and playing the actual mechanistic effect on the
cellular properties observed. Several genes involved in cell
proliferation and oncogenesis are present in the vicinity of the
TOP1 gene and belong to the same haplotypic block: they could
well be the true responsible for the association observed between
TOP1 polymorphisms and drug cytotoxicity. This is especially the
case for the gene ZHX3, which encodes a zinc-finger protein
involved in the repression of transcription. There is a common
non-synonymous polymorphism on this gene (Ser310Asn), with a
rare allele frequency of 0.208 in Caucasians, which is significantly
associated with the variant haplotypes of the TOP1 gene, and
whose functionality is not known and should be explored (http://
www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs¼17265513).
Nevertheless, even if the mechanism relating TOP1 polymor-
phisms to drug cytotoxicity remains unidentified, it might be of
interest to identify such associations, that may be used as
predictive factors of drug activity, once the in vitro observation
has been transferred to the clinical setting. We are planning
retrospective studies on DNA samples from cancer patients who
have been treated, for instance, with combinations of antifolates
(such as raltitrexed) and Top1 inhibitors (such as irinotecan) in
order to validate our observations.
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